Transparency Life Sciences combines crowdsourcing and mobile health technology to advance drug candidates through clinical trials with reduced reliance on physical study sites. Its platform includes Transparency Protocol Crowdsourcing™, Transparency Virtual Trials™, and Transparency Personalized Digityping™ to co-design protocols, run virtual trials, and digitally phenotype patients. The company emphasizes patient and regulatory relevance and aims to limit geographic scope of enrollment through digital tools. Led by co-founder and CEO Tomasz Sablinski, MD, PhD, TLS completed a $5.0M Series A to support growth. The new funding will be used to expand the technology platform and clinical operations infrastructure and to drive commercialization of its integrated digital clinical development approach. TLS is based in New York City and positions its services to make clinical trials more efficient and relevant to real-world medical needs.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2018